uspC Antibody

What are USP (Ubiquitin Specific Protease) antibodies and what cellular processes do they help investigate?

USP antibodies are research tools that detect and study Ubiquitin Specific Proteases, which are deubiquitinating enzymes (DUBs) that remove ubiquitin from target proteins. These enzymes comprise approximately 60% of all DUBs and represent the largest and most varied DUB family . USP antibodies help researchers investigate:

• Immune response regulation in tumor microenvironments

• Cancer pathways and immunotherapy efficacy

• Protein degradation mechanisms

• Cell cycle regulation and mitophagy

• Endoplasmic reticulum stress responses

Different USP family members (such as USP25, USP30, USP35) have distinct biological functions. For example, USP35 plays roles in "cell cycle regulation, mitophagy or endoplasmic reticulum stress" , while USP25 functions in "inflammation, immune response" and modulates "the Wnt/beta-catenin pathway by deubiquitinating and stabilizing tankyrases" .

How are antibodies against USP proteins validated for research applications?

The gold standard for USP antibody validation employs an isogenic cell model system:

"The optimal antibody testing methodology involves using an appropriately selected wild type cell and an isogenic CRISPR knockout (KO) version of the same cell as the basis for testing, yielding rigorous and broadly applicable results."

Comprehensive validation includes testing across multiple applications:

• Western blot (WB)

• Immunoprecipitation (IP)

• Immunohistochemistry (IHC)

• Immunofluorescence (IF)

A large-scale study assessed 614 commercial antibodies for 65 neuroscience-related proteins using this approach, providing important benchmarks for antibody performance . This standardized characterization process allows side-by-side comparison of antibodies against the same target from multiple vendors.

What are the recommended dilutions and applications for USP antibodies in standard laboratory techniques?

Based on manufacturer specifications, different USP antibodies have optimized conditions for various applications. For example:

Importantly, manufacturers emphasize: "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" as performance can be "Sample-dependent" .

How do researchers address variability in USP antibody performance across different experimental applications?

Antibody performance often varies dramatically between applications. Research has shown limited correlation between an antibody's performance in different techniques . To address this variability:

• Perform application-specific validation: An antibody that works well in Western blot may fail in immunofluorescence.

• Test multiple antibodies: When possible, evaluate multiple antibodies against the same target:
  "Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners" provides the most reliable assessment .

• Include proper controls: For each application, include positive controls (cell lines known to express the target) and negative controls (knockout cells or isotype controls).

• Standardize protocols: Develop detailed protocols with all critical parameters specified.

• Use reference standards: Incorporate USP monoclonal antibody reference standards as controls when possible .

What methodological considerations are important when using USP antibodies to study deubiquitinating enzyme function in cancer pathways?

USPs play significant roles in cancer immunotherapy by "regulating immune cell function and immune response in tumor microenvironment (TME)" . When studying USPs in cancer:

• Select appropriate model systems:

  • Choose cell lines based on target expression levels

  • Consider cancer models relevant to the specific USP being studied

  • Validate antibody specificity in each model system

• Consider combinatorial approaches:
  Studies have shown that USP inhibitors combined with other therapies can yield synergistic effects. For example, "When used in combination, an adenovirus-based vaccine and P5091 (USP7 inhibitor) in a mouse CT26 xenograft model displayed better outcomes than either drug used alone" .

• Assess relevant functional outcomes:

  • Cytokine production (e.g., IFN-γ, TNF-α, IL-10)

  • Immune cell infiltration and activity

  • Tumor growth parameters

• Integrate genomic and proteomic data:
  Correlate antibody-based detection with RNA expression data when possible to strengthen findings.

How can researchers effectively distinguish between closely related USP family members in experimental systems?

Discriminating between related USP proteins requires careful experimental design:

• Epitope selection: Choose antibodies targeting unique regions not conserved across USP family members.

• Validation in knockout systems: Use CRISPR-Cas9 generated knockout cells for each specific USP protein.

• Expression profiling: Consider tissue-specific expression patterns. For example:

  • "Isoform USP25a is found in most adult and fetal tissues"

  • "Isoform USP25b is found in all tissues except heart and skeletal muscle"

  • "Isoform USP25m is heart and skeletal muscle-specific"

• Confirmatory techniques: Employ orthogonal methods like mass spectrometry or RNA analysis to confirm antibody specificity.

• Dilution optimization: Test antibody dilution series to maximize specific binding while minimizing cross-reactivity.

What are the key considerations for optimizing Western blot protocols using USP antibodies?

USP proteins often have high molecular weights and complex post-translational modifications, requiring specific Western blot optimization:

• Sample preparation:

  • Use appropriate lysis buffers (often containing deubiquitinase inhibitors)

  • Ensure complete protein denaturation for accurate molecular weight detection

  • Include protease and phosphatase inhibitors

• Gel selection and transfer conditions:

  • Use lower percentage gels for high molecular weight USPs (e.g., USP25: 125 kDa )

  • Consider longer transfer times or specialized transfer methods for large proteins

• Antibody dilution optimization:

  • Start with manufacturer recommendations (e.g., 1:500-1:2000 for USP25 )

  • Perform titration experiments to determine optimal concentration

• Detection method selection:

  • Choose detection system based on expected protein abundance

  • Consider enhanced chemiluminescence for low abundance targets

• Controls:

  • Include positive controls (e.g., "BxPC-3 cells, mouse cerebellum tissue, K-562 cells" for USP25 )

  • Use knockout or knockdown samples as negative controls when available

What validation strategies are essential when using USP antibodies in immunohistochemistry for tissue samples?

For reliable immunohistochemistry results with USP antibodies:

• Optimize antigen retrieval:
  Specific conditions are often required; for example, USP25 antibody validation suggests "antigen retrieval with TE buffer pH 9.0" with an alternative option of "citrate buffer pH 6.0" .

• Titrate antibody concentration:
  Test a dilution series (e.g., 1:200-1:800 for USP25 in IHC ).

• Include appropriate controls:

  • Positive control tissues known to express the target

  • Negative controls (omitting primary antibody)

  • Isotype controls to assess non-specific binding

• Validate staining pattern:

  • Compare with expected subcellular localization

  • Assess specificity using knockout/knockdown tissues when available

• Optimize detection system:
  Select appropriate secondary antibodies and visualization methods based on target abundance and tissue type.

How can researchers ensure reproducibility when using USP antibodies across different experimental systems?

Maintaining reproducibility requires systematic approaches:

• Standardize protocols:
  Develop detailed SOPs covering all experimental steps, from sample preparation to data analysis.

• Document antibody information:
  Record catalog numbers, lot numbers, dilutions, and incubation conditions.

• Use reference standards:
  "USP monoclonal antibody reference standards...can be used for many purposes including: as an independent control material for method development, training, and method transfer; as an internal assay control" .

• Implement quality control measures:
  Regularly test antibody performance using control samples.

• Cross-validate results:
  Use multiple antibodies against the same target when possible.

• Compare with orthogonal methods:
  Correlate antibody-based results with RNA expression or mass spectrometry data.

How are size exclusion chromatography (SEC) methods used to analyze antibody quality for USP research?

Size exclusion chromatography (SEC) is critical for ensuring antibody quality in USP research:

"SEC can be used to measure LMW variants, monomer, and high-molecular weight (HMW) variants in the same analysis yielding a measure of monomeric purity. [It] robustly differentiates between Monomer, HMWS (aggregates) and LMWS (fragments)."

SEC analysis ensures antibody reagent quality, which is essential because "antibody aggregation can lead to immunogenicity" and ">99% purity is crucial" .

The transition from traditional HPLC to UHPLC methods has further improved analysis:
"UHPLC is an advanced separation technique that allows for shorter run times, less amount of sample, better chromatographic separation, and increased throughput as compared to traditional HPLC."

What are USP monoclonal antibody reference standards and how are they used in antibody-based research?

USP has developed four monoclonal antibody Reference Standards:

• mAb System Suitability

• mAb 001

• mAb 002

• mAb 003

These standards provide "a range of reference materials with different physico-chemical properties" and are characterized by:

These standards serve multiple purposes:

• "Independent control material for method development, training, and method transfer"

• "Internal assay control"

• "Standardization of physico-chemical testing, such as intact mass, charge heterogeneity, size variants, purity, and glycan analyses"

What quality attributes are measured in characterizing USP monoclonal antibody reference standards?

USP monoclonal antibody reference standards undergo comprehensive characterization:

HMWS = High Molecular Weight Species, LMWS = Low Molecular Weight Species

How are USP antibodies utilized in cancer research to understand deubiquitination in tumor development?

USP antibodies serve several critical functions in cancer research:

• Expression profiling:
  Detect and quantify USP expression in tumor versus normal tissues.

• Mechanistic studies:
  "USPs can regulate the efficacy of immunotherapy through modulating immune cell function and immune response in tumor microenvironment (TME)" . Antibodies help track these mechanisms.

• Therapeutic target validation:
  For example, "USP7 inhibition was capable of potentiating the efficacy exhibited by the adenovirus-based tumor vaccine and the anti-PD-1 monoclonal antibody therapy in mice with TC1 lung tumor" .

• Biomarker development:
  Studies like those examining Trop-2 expression in Uterine Serous Papillary Carcinoma used antibody-based methods including "immunohistochemistry (IHC) in a total of 23 USPC" and "flow cytometry and real-time-PCR" .

• Therapeutic antibody development:
  Research on humanized anti-Trop-2 monoclonal antibody (hRS7) demonstrated "a high level of antibody-dependent cellular cytotoxicity (ADCC)" against cancer cells.

What role do USP proteins and their antibody-based detection play in neuroscience research?

USP proteins have emerged as important factors in neurological disorders:

A major antibody validation study focused on "65 neuroscience-related proteins" including:

• "32 Alzheimer's disease (AD)-related proteins"

• "22 proteins nominated within the amyotrophic lateral sclerosis (ALS) Reproducible Antibody Platform project"

• "5 Parkinson's disease (PD)-linked proteins"

This focus indicates the importance of USP proteins in:

• Neurodegenerative disease mechanisms

• Protein quality control in neurons

• Neuroinflammatory processes

Researchers use USP antibodies to:

• Map expression patterns in neural tissues

• Study protein degradation pathways in neurodegeneration

• Investigate potential therapeutic targets

• Develop biomarkers for neurological disorders

How do approaches to functional antibody claims differ between Europe and the US, and what implications does this have for research?

Important regional differences exist in antibody patent protection:

These differences impact how researchers should document and publish work on novel antibodies when patent protection is a consideration .

What are the current approaches to antibody discovery for generating high-quality USP antibodies?

Modern antibody discovery involves sophisticated methodologies:

• Target research:
  "Extensive basic research to understand the target antigen thoroughly. Researchers study its structure, function, and role in various diseases."

• Antibody generation approaches:

  • Traditional immunization: "Introducing the target antigen into a host organism, typically a mouse or rabbit"

  • Non-animal systems: "Yeast cells or mammalian cell lines...with viral vectors or plasmids"

• Screening technologies:
  "High-throughput screening techniques...allow for the rapid assessment of a large number of antibodies in various formats"

• Characterization and optimization:
  "Rigorous characterization, where binding properties and functional attributes are assessed...determining the epitope specificity and the ability to bind to the antigen with high affinity"

• Validation in biological systems:
  "Preclinical studies, often involving in vitro and in vivo experiments, assess the antibodies' performance in realistic biological systems"

The newest approach combines traditional antibody generation with genetic engineering:
"USC scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy cancer cells or HIV" .